Clinical Trial Detail

NCT ID NCT03007732
Title Pembrolizumab in Combination With Intratumoral SD-101 Therapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Lawrence Fong
Indications

prostate adenocarcinoma

Therapies

Pembrolizumab + SD-101

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.